Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090829 | 0.89 | CES2 (0.55) | CES2CES1PDE2AACP3 | |
| SCHEMBL10392935 | 0.87 | CES2 (0.53) | CES2CES1PDE2AACP3 | |
| SCHEMBL2276839 | 0.83 | KIF11 (0.58) | CYP19A1CES2CES1ACP3 | |
| SCHEMBL6564721 | 0.82 | PTPN5 (0.44) | CES2CES1PPARGPDE2AMEN1 | |
| SCHEMBL196588 | 0.82 | CYP19A1 (0.55) | CYP19A1CES2CES1MEN1KMT2A | |
| SCHEMBL28777340 | 0.82 | CYP19A1 (0.55) | CYP19A1CES2CES1MEN1KMT2A | |
| SCHEMBL1426754 | 0.82 | TSHR (0.50) | CYP19A1 | |
| SCHEMBL477425 | 0.81 | ACP3 (0.59) | CNR2CES2CES1ACP3 | |
| SCHEMBL1350356 | 0.81 | PAX8 (0.49) | CYP19A1CES2CES1PDE2AACP3 | |
| SCHEMBL477694 | 0.81 | ACP3 (0.59) | CNR2CES2CES1ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | CNR2 42/4885CYP19A1 611/4885CES2 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.